Premium
Cost‐effectiveness analysis of sacral nerve stimulation as treatment for severe irritable bowel syndrome
Author(s) -
Tipsmark L. S.,
Fassov J.,
Lundby L.,
Laurberg S.,
Ehlers L.,
Krogh K.
Publication year - 2016
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/codi.13149
Subject(s) - medicine , irritable bowel syndrome , cost effectiveness analysis , perspective (graphical) , cost effectiveness , quality of life (healthcare) , quality adjusted life year , physical therapy , intensive care medicine , surgery , risk analysis (engineering) , artificial intelligence , nursing , computer science
Aim Early results from sacral nerve stimulation ( SNS ) for severe irritable bowel syndrome ( IBS ) are promising but estimates of cost‐effectiveness are lacking. Our object was to perform a cost‐effectiveness analysis for SNS as an alternative to no treatment of IBS . Method This retrospective analysis was based on the results from a randomized controlled crossover study with a cost‐utility analysis performed on patient‐level data and modelling of censored data over a projected period of time of up to 20 years. The analysis was conducted on an intention‐to‐treat approach. For estimation of the uncertainty of the incremental cost‐effectiveness ratio a bias corrected bootstrap analysis was performed. Results Cost‐effectiveness was not reached for 4 years after permanent implantation (£31 270 per quality‐adjusted life years), which was the upper limit for patient follow‐up, but our data imply a cost‐effectiveness from a 7‐year perspective onwards. Conclusion The study indicates the SNS treatment for IBS is cost effective from a 7‐year perspective onwards.